Business News • PR NewsWire • Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML

Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML

Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML

EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the disease 24-month analysis confirms Tasigna induces deeper and more durable cytogenetic and molecular res

View More : http://www.prnewswire.com/news-releases/longer-term-phase-iii-data-show-novartis-drug-tasigna-continues-to-surpass-gleev...

Releted News by prnewswire

Bookie Barlow Backed for Corrie Exit

LeapNgo.com Rings in the Holidays with 3 $100,000 Total Cash Prize Contests